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The anthraquinones emodin and aloe-emodin are abundant in rhubarb. Several lines of evidence indicate that emodin and aloe-
emodin have estrogenic activity as phytoestrogens. However, their effects on estrogen receptor 𝛼 (ER𝛼) activation and breast
cancer cell growth remain controversial. The goal of this study is to investigate the effects and molecular mechanisms of emodin
and aloe-emodin on breast cancer cell proliferation. Our results indicate that both emodin and aloe-emodin are capable of
inhibiting breast cancer cell proliferation by downregulating ER𝛼 protein levels, thereby suppressing ER𝛼 transcriptional activation.
Furthermore, aloe-emodin treatment led to the dissociation of heat shock protein 90 (HSP90) and ER𝛼 and increased ER𝛼
ubiquitination. Although emodin had similar effects to aloe-emodin, it was not capable of promoting HSP90/ER𝛼 dissociation and
ER𝛼 ubiquitination. Protein fractionation results suggest that aloe-emodin tended to induce cytosolic ER𝛼 degradation. Although
emodin might induce cytosolic ER𝛼 degradation, it primarily affected nuclear ER𝛼 distribution similar to the action of estrogen
when protein degradation was blocked. In conclusion, our data demonstrate that emodin and aloe-emodin specifically suppress
breast cancer cell proliferation by targeting ER𝛼 protein stability through distinct mechanisms. These findings suggest a possible
application of anthraquinones in preventing or treating breast cancer in the future.
1. Introduction
Many phytochemicals derived from plants, including
anthraquinone, have been reported to have anticancer
potential. The anthraquinone derivatives emodin (1,3,8-
trihydroxy-6-methylanthraquinone) and aloe-emodin (1,8-
dihydroxy-3-hydroxyl-methylanthraquinone) are the main
bioactive components of rhubarb (Rheum palmatum), which
has been used in traditional Chinese medicine [1]. Aloe-
emodin is also abundant in the leaves of the common plant
Aloe vera [2]. Emodin has been widely investigated for its
antibacterial [3], anti-inflammatory [4], and antiproliferative
effects in several types of cancer [1]. Notably, emodin may
downregulate androgen receptor (AR) and lead to the
inhibition of prostate cancer cell growth [5], suggesting
that anthraquinone derivatives might modulate steroid
receptor activity. Several lines of evidence indicate that
emodin and aloe-emodin have estrogenic activity and
modulate breast cancer cell proliferation as phytoestrogen
compounds [6, 7]. However, the pharmacological effects
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and molecular mechanisms of emodin and aloe-emodin in
estrogen receptor 𝛼 (ER𝛼) modulation and breast cancer cell
growth remain elusive.
Breast cancer is a commonmalignancywith high lethality
in women. Because ER𝛼 activation plays an important role in
the initiation, development, and progression of breast cancer,
estrogen replacement therapy is the most common strategy
to suppress breast cancer progression [8]. By mimicking the
structure of estrogen, synthetic estrogen-like compounds are
used to compete for the binding of endogenous estrogen
with ER𝛼 and therefore inhibit ER𝛼-dependent growth of
breast cancer cells [9, 10]. However, synthetic estrogens have
side effects that increase the risk of cancer development due
to unselective estrogenic action [11]. Although the potency
of natural phytoestrogens is generally lower than that of
synthetic estrogens in terms of estrogenic action, natural
phytoestrogens are relatively safer with fewer side effects
[12]. Therefore, studies investigating the effects and molec-
ular mechanisms of natural herbal medicines that contain
phytoestrogens as potential treatments to breast cancer are of
interest.
We found that the inhibition of proliferation by emodin
and aloe-emodin was ER𝛼-dependent in breast cancer cell
lines. Importantly, aloe-emodin treatment promotes ER𝛼
protein degradation by repressing the association of ER𝛼 and
heat shock protein 90 (HSP90). Moreover, the dissociated
ER𝛼 is ubiquitinated and targeted for proteasome-dependent
degradation in the cytosol. The findings for aloe-emodin
are distinct from those for emodin. Based on the above
observations, these two anthraquinones could potentially be
used as specific phytoestrogens to treat breast cancer.
2. Materials and Methods
2.1. Cell Lines and Cell Culture. The human breast cancer
cell lines MCF-7 and MDA-MB-453 were obtained from the
Bioresource Collection and Research Center (BCRC), Food
Industry Research andDevelopment Institute, Taiwan.MCF-
7 cells were grown in minimum essential medium (Gibco,
Carlsbad, CA, USA) containing 10% fetal bovine serum
(Gibco), 1.5 g/L NaHCO
3
, 0.1mM nonessential amino acids
(Gibco), 1mM sodium pyruvate (Gibco), and 1% penicillin-
streptomycin (Sigma, St. Louis, MO, USA). MDA-MB-453
cells weremaintained in Dulbecco’s modified Eagle’s medium
(Gibco) supplemented with 10% fetal bovine serum, 1.5 g/L
NaHCO
3
, and 1% penicillin-streptomycin. All cells were
incubated at 37∘C in a humidified atmosphere with 5% CO
2
.
2.2. Cell Viability Assay. Cells were incubated for 24 hours
after attachment. Cell numbers were calculated by direct
counting of cells, excluding cells that stained positive for 0.2%
trypan blue stain (Sigma, St. Louis, MO, USA) [13]. Cells
were treated with different concentrations of aloe-emodin
or emodin (ChromaDex, Irvine, CA, USA) for the indicated
number of days, and then, the 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT, Sigma, St. Louis, MO,
USA) assay was used to quantify cell proliferation. The MTT
stock solution (5mg/mL) was diluted to 0.5mg/mL with
complete culturemedium, and 0.1mLwas added to eachwell.
The yellow MTT was converted to blue formazan by living
cells, a reaction that is dependent on mitochondrial enzyme
activity. After using DMSO to dissolve the blue formazan, the
absorbance of converted MTT could be measured at 570 nm
𝜆 [14].
2.3. Cell Fractionation and Western Blot Analysis. Cells were
collected using a rubber scraper and homogenized with
Na
3
VO
4
diluted in PBS (1 : 100). After centrifugation, cells
were resuspended with lysis buffer as previously described
[15–19], and protease inhibitor cocktail (Roche Applied Sci-
ence, Mannheim, Germany) was added, followed by incuba-
tion on ice for 45 minutes. The cell lysate was centrifuged,
and the supernatant was collected as total protein extract.
The protein extract was mixed with sample buffer and boiled
for 10 minutes. Then, western blotting was performed as
previously described [19, 20]. Briefly, SDS-polyacrylamide
gel electrophoresis (SDS-PAGE)was performed, and proteins
were transferred from the SDS-PAGE gel onto a polyvinyli-
dene fluoride (PVDF) membrane. Primary antibodies were
incubated with the membrane overnight, and horseradish
peroxidase- (HRP-) conjugated secondary antibodies (Jack-
son ImmunoResearch Laboratory, West Grove, PA, USA)
were applied. The ECL (western lighting chemiluminescence
reagent plus, PerkinElmer Life Sciences, Shelton, CT, USA)
reaction was performed, and the membranes were exposed
to X-ray films to visualize protein staining (Fujifilm, Tokyo,
Japan). Antibodies directed against the following proteins
were used in this study: poly(ADP-ribose) polymerase (PARP,
06-557, Upstate Biotechnology, Lake Placid, NY, USA), 𝛼-
tubulin (05-829, Upstate Biotechnology), ER𝛼 (sc-543 and
sc-8005, Santa Cruz Biotechnology, Santa Cruz, CA, USA),
cyclin D1 (sc-20044, Santa Cruz Biotechnology), HSP 90𝛼/𝛽
(sc-59577, Santa Cruz Biotechnology), ubiquitin (sc-8017,
Santa Cruz Biotechnology), and 𝛽-actin (MAB1501, Milli-
pore, Temecula, CA, USA). The quantification software used
was MCID Image Analysis Evaluation.
2.4. Immunoprecipitation. Cell lysate was extracted in lysis
buffer, and immunoprecipitation was performed as previ-
ously described [19]. Briefly, the beads/antibody precipitated
complex was prepared by mixing Protein G Mag Sepharose
Xtra beads (GEHealthcare,Waukesha,WI, USA) and specific
antibody at 10 𝜇g : 1𝜇g for 2 h at room temperature. Cell
lysates were mixed with beads/antibody for 12 h at 4∘C, and
protein was isolated by precipitation under magnetic attrac-
tion with three rounds of PBST washes. The precipitated
proteins were analyzed by western blotting after denaturation
following dilution in sample buffer and boiling for 10minutes.
2.5. Quantitative Real-Time PCR. Total RNA was extracted
from cells using a Miniprep Purification Kit (Genemark,
Taipei, Taiwan), and reverse transcription-PCR was per-
formed using a High-Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Foster City, CA, USA) following
the standard procedures recommended by the manufacturer.
For reverse transcription, 2𝜇g of total RNA was used as the
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first-strand cDNA template for the subsequent amplification
procedure. The following primers were used to amplify
the cDNAs: ER𝛼 (5󸀠-TGGAGATCTTCGACATGCTG-3󸀠 and
5󸀠-TCCAGAGACTTCAGGGTGCT-3󸀠) [21] and 𝛽-actin (5󸀠-
TTGCCGACAGGATGCAGAA-3󸀠 and 5󸀠-GCCGATCCA-
CACGGAGTACT-3󸀠). cDNA and primers weremixedwithin
FastStart Universal SYBR Green Master (Roche Applied
Science) and measured using a real-time PCR instrument
(Applied Biosystems). Data presented by Ct values were
analyzed and adjusted relative to levels of the 𝛽-actin house-
keeping gene.
2.6. Transfection and Reporter Assays. Cells were plated for at
least 24 h and had reached 80% confluency prior to transfec-
tion. Expression plasmidwas premixedwithin Lipofectamine
2000 Reagent (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s instructions. The liposome/plasmid com-
plex was transfected into MCF-7 cells incubated with Opti-
MEM (Gibco) for 6 h, and then culture medium was added
for exogenous protein expression. The pCMV5-ER𝛼 expres-
sion plasmid was kindly provided by Professor Chih-Yang
Huang, Graduate Institute of Basic Medical Science, China
Medical University, Taichung, Taiwan. A reporter assay was
performed to detected ER𝛼 transcriptional activity after cells
were transfectedwith 3×ERE-containing-promoter luciferase
reporter gene (pGL2-TK-3 × ERE, gift from Dr. Chih-Yang
Huang, China Medical University, Taichung, Taiwan) and
internal control pSV-𝛽-galactosidase expression plasmid (gift
from Dr. Jeremy J. W. Chen, National Chuang Hsing Uni-
versity, Taichung, Taiwan). Reporter gene luciferase produc-
tion was performed using the Dual-Light System (Applied
Biosystems), andmeasurements were performed using a 1420
Multilabel Counter VICTOR3 instrument (PerkinElmer Life
Sciences). The raw data were normalized to 𝛽-galactosidase
activity to control for varying transfection efficiencies [19].
2.7. Statistics. All values are presented as themean± standard
error of themean (SEM). In all cases, Student’s 𝑡-test was used
to assess the results of cell proliferation and reporter assays.
A difference between two means was considered statistically
significant when 𝑃 < 0.05.
3. Results
3.1. ER𝛼 Is Important for the Growth Inhibition Induced by
Emodin and Aloe-Emodin. The effects of different concen-
trations (0, 6, 12.5, 25, 50, or 100𝜇M) of emodin and aloe-
emodin on the growth of the ER𝛼-positive breast cancer
cell line MCF-7 were determined by cell number counting
(0–6 days) and MTT assays (4 days). Emodin and aloe-
emodin treatment led to dose-dependent suppression of
MCF-7 growth (Figures 1(a) and 1(b)). Notably, 12.5 𝜇M or
higher concentrations of aloe-emodin had stronger effects
on MCF-7 growth compared to the same dosage of emodin.
MTT assays showed significant inhibition of MCF-7 pro-
liferation in a dose-dependent manner following emodin
treatment at concentrations of 25 to 100𝜇M (Figure 1(c)) and
of aloe-emodin treatment at concentrations of 6 to 100 𝜇M
(Figure 1(d)). Whereas emodin was more effective against
the ER𝛼-negative breast cancer cell line MDA-MB-453 than
against MCF-7 (Figure 1(e)), the inhibitory effects of aloe-
emodin on the growth of MDA-MB-453 was moderate com-
pared to the effects on MCF-7 cells (Figure 1(f)). In which,
25 𝜇M of aloe-emodin was not able to affect MDA-MB-453
cell proliferation (Figure 1(f)), while 25 𝜇M of emodin sig-
nificantly reduced that cell proliferation (Figure 1(e)) implies
that the effects of aloe-emodin might be associated with ER𝛼
and distinct to emodin. To further investigate whether ER𝛼
was involved in the inhibitory effects of the emodin and aloe-
emodin treatments, the effects of emodin and aloe-emodin
on the growth of MCF-7 with or without ER𝛼 overexpres-
sion were investigated. Following a 25𝜇M treatment with
emodin (Figure 1(g)) or aloe-emodin (Figure 1(h)), the ER𝛼-
overexpressing cells were more sensitive to drug treatments
compared to control cells. Similar results were also observed
in another ER𝛼-positive cell line, T47D (data not shown).
These data indicate that ER𝛼 protein plays an important
role in the emodin- and aloe-emodin-induced suppression of
breast cancer cell proliferation, although the potency of these
two compounds are slightly different.
3.2. Emodin and Aloe-Emodin Decrease ER𝛼 Protein Levels
in a Time- and Dose-Dependent Manner. ER𝛼 activation
is triggered by estrogen and promotes the initiation and
progression of breast cancer [22, 23]. ER𝛼 protein levels
were detected following treatment with various dosages of
emodin or aloe-emodin (0–100 𝜇M, Figures 2(a) and 2(c))
for different time intervals (0–48 h, Figures 2(b) and 2(d)).
The quantitative results were provided in the lower panels of
the accompanying figures. The data suggest that emodin and
aloe-emodin triggered a decrease in ER𝛼 protein level in a
time- and dose-dependent manner.
3.3. Emodin and Aloe-Emodin Decrease Both Nuclear and
Cytosolic ER𝛼 and Inhibit ER𝛼 Activation. Because ER𝛼
protein levels were affected by emodin and aloe-emodin, the
activation status of ER𝛼 was investigated. Fractionation of
cellular protein was performed and indicated that emodin
and aloe-emodin repressed both the nuclear and cytosolic
distribution of ER𝛼 protein (upper panels in Figures 3(a)
and 3(b)). The quantitative results are presented in the
lower panels of Figures 3(a) and 3(b). Additionally, cytosolic
ER𝛼 was more sensitive to treatment than nuclear ER𝛼.
An ER𝛼 reporter assay was performed in MCF-7 cells.
The data showed that aloe-emodin significantly inhibited
ER𝛼-targeted promoter activity in a dose-dependent manner
(Figure 3(d)). Compared to aloe-emodin, emodin in high
dosages (25–100𝜇M) moderately inhibited ER𝛼 activation,
whereas low dosages of emodin (6 and 12.5 𝜇M) tended to
increase ER𝛼 activation. Furthermore, the expressions of ER𝛼
downstream genes might be affected by those two com-
pounds. Figures 3(e) and 3(f) were the evidence indicating
that the protein expression of cyclin D1 which is one of
ER𝛼-regulated protein was indeed decreased by treatments
of 25𝜇M emodin or 25 𝜇M aloe-emodin for 48 h.
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Figure 1: Continued.
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Figure 1: Emodin and aloe-emodin inhibit breast cancer cell growth. MCF-7 cells were treated with various concentrations of emodin (a)
or aloe-emodin (b) for 0 to 6 days. Cell numbers were calculated by trypan blue staining. (c–f) MCF-7 and MDA-MB-453 cells were treated
with various concentrations of emodin or aloe-emodin for 4 days. Cell proliferation was determined by an MTT assay. The control cell
proliferation rate was set at 1. MCF-7 cells were transiently transfected with empty vector or pCMV5-ER𝛼 and treated with 25𝜇M emodin
(g) or aloe-emodin (h) for 4 days. The transfected efficiencies of ER𝛼 overexpression and cell numbers were detected by western blotting and
trypan blue staining, respectively. The results were presented as the mean ± SEM. ∗ and ∗∗ correspond to 𝑃 < 0.05 and 𝑃 < 0.01, respectively,
versus the control group or empty vector group.
3.4. Emodin and Aloe-Emodin Treatment Leads to Decreased
ER𝛼 Protein through Proteasomal Degradation. Because ER𝛼
protein levels were affected by both emodin and aloe-emodin
in the previous experiments, the gene expression and protein
stability of ER𝛼 were investigated. First, ER𝛼 messenger
RNA expression was detected by quantitative real-time PCR
following treatment. We found that treatments of 25𝜇M
emodin and 25𝜇M aloe-emodin for 24 h did not have a
significant effect compared to the control group (Figure 4(a)).
Second, because ubiquitin-proteasome-dependent degrada-
tion is the main process involved in ER𝛼 proteolysis [23], the
proteasome inhibitorMG132was used to prevent ER𝛼protein
degradation, and drug effects can be observed. The results
of this experiment indicated that MG132 could rescue ER𝛼
degradation after emodin or aloe-emodin treatment (Figures
4(b) and 4(c)).These findings suggest that the decreased ER𝛼
protein levels observed following emodin or aloe-emodin
treatment resulted from proteasome degradation.
3.5. Aloe-Emodin Promotes the Dissociation of ER and Heat
Shock Protein 90 and Causes ER𝛼 Ubiquitination. ER𝛼 is
processed by ubiquitination after disassociating from heat
shock protein 90 (HSP90) [24]. Using immunoprecipitation
in the presence of MG132 to prevent protein degradation, we
found that aloe-emodin apparently blocked the protein inter-
action between ER𝛼 and HSP90 (Figure 5(a)); however, the
effect induced by emodin was not as significant (Figure 5(b)).
The quantitative graphs were provided in the lower panels of
accompanying figures. Subsequently, ER𝛼 ubiquitination fol-
lowing drug treatmentwas investigated by detecting the levels
of ubiquitinated ER𝛼 in drug-treated cell extracts following
MG132 administration. The data indicated that aloe-emodin
treatment enhanced ubiquitin-conjugated ER𝛼 levels, and
protein degradation was prevented by MG132 treatment
regardless of whether ER𝛼 or ubiquitin was immunoprecipi-
tated first (Figure 5(c)). Although emodin slightly promoted
ER𝛼/HSP90 dissociation (Figure 5(b)), no increase in ER𝛼
ubiquitination was observed following emodin treatment
(Figure 5(d)). The related quantitative results were shown
in the lower panels. It suggests that ubiquitination was not
required for emodin-induced ER𝛼 degradation by protea-
some. These results indicate that aloe-emodin specifically
reduces ER𝛼 protein levels by promoting ER𝛼 ubiquitination,
which results in proteasome-dependent degradation.
3.6. Comparison of Emodin/Aloe-Emodin and Estrogen on
ER𝛼 Behaviors. Ligand binding by estrogen or estrogen-
like molecules promotes ER𝛼 transactivation, during which
ER𝛼 first dissociates from HSP90 in the cytoplasm and
then translocates into the nucleus [8]. Because the effects of
aloe-emodin and emodin on the ER𝛼 ubiquitination process
are distinct (Figure 5), it is of interest to understand how
the effects of these two compounds compare to those of
estrogen to mediate ER𝛼 behavior. Immunoprecipitation
experiment results indicate that aloe-emodin had similar
effects to synthetic estrogen (estradiol benzoate (EB)) on
ER𝛼/HSP90 dissociation (Figure 6(a)), whereas emodin did
not (Figure 5(b)). However, in contrast to EB treatment,
aloe-emodin treatment led to a decrease in the nuclear
and cytoplasmic levels of ER𝛼 protein. Furthermore, the
decrease in ER𝛼 protein levels following aloe-emodin treat-
ment was blocked by MG132, suggesting that aloe-emodin
promotes ER𝛼 degradation (Figure 6(b)). Comparing the
data in Figure 3(b), we suggest that aloe-emodin preferen-
tially induces ER𝛼 degradation in the cytoplasm of breast
cancer cells. Interestingly, nuclear ER𝛼 was increased by
emodin treatment, and protein degradation was prevented
by MG132 (Figure 6(c)), suggesting that although emodin
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Figure 2: Emodin and aloe-emodin reduce ER𝛼 protein levels. MCF-7 cells were treated with emodin or aloe-emodin in a dose-dependent
manner for 24 h (a, c) and via a time course using 25 𝜇M of the drug (b, d). ER𝛼 protein levels were detected by western blotting. 𝛽-Actin
was used as an internal control. The quantification of ER𝛼 levels is presented as fold increase or decrease compared to control levels and was
evaluated in three independent experiments. The results were presented as the mean ± SEM. ∗ and ∗∗ correspond to 𝑃 < 0.05, and 𝑃 < 0.01,
respectively, versus the control group.
induces ER𝛼 degradation in both the nucleus and cyto-
plasm (compared to Figure 3(a)), it seems that emodin is
able to promote ER𝛼 translocation into the nucleus, which
is in contrast to the actions of aloe-emodin. This might
explain why low concentrations of emodin showed slight
stimulation in the ER𝛼 reporter assay (Figure 3(c)). Taken
together, these results demonstrate that aloe-emodin induces
the dissociation of ER𝛼/HSP90 and subsequently promotes
ER𝛼 ubiquitin-proteasome-dependent degradation in the
cytoplasm, thereby inhibiting ER𝛼 translocation into nucleus,
where ER𝛼 would otherwise be activated as a positive
modulator.
4. Discussion
Breast cancer is a commonmalignancy in women, and estro-
gen plays an important role in early cancer development [25].
Estrogen, which usually denotes 17𝛽-estradiol (E2), binds to
its primary receptor ER𝛼 and stimulates ER𝛼 transcriptional
activity to regulate downstream gene expression and cell
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growth [26, 27]. Tamoxifen is designed to interfere with E2
binding and thus block ER𝛼 transcriptional activity to treat
ER𝛼-dependent diseases such as breast cancer [28]. However,
alternative compounds that are safer and associated with
fewer side effects than Tamoxifen are desired. Numerous
studies suggest that phytoestrogens possess organ-specific
estrogenic and antiestrogenic effects [29]. Phytoestrogens
mainly consist of isoflavones, such as genistein and daidzein,
and are used in the treatment of menopausal symptoms
as well as breast cancer [30, 31]. In this study, we provide
evidence indicating that two phytoestrogens, emodin and
aloe-emodin, might significantly inhibit the proliferation of
ER𝛼-positive breast cancer cells through ER𝛼 degradation.
Although both drugs had dose-responsive effects on inhibit-
ing proliferation of breast cancer cells, low doses (25𝜇M or
less) of aloe-emodin could not affect proliferation of ER𝛼-
negative cells (Figure 1(f)). Therefore, 25 𝜇M of drugs were
utilized in other experiments (Figure 3 to Figure 6). Inter-
estingly, both compounds had inhibitory effects on ER𝛼, but
they utilized different inhibitory mechanisms. Aloe-emodin
inhibited ER𝛼 activation through HSP90/ER𝛼 dissociation
and ubiquitin-dependent degradation, whereas emodin did
not share the same molecular pathway. Therefore, these
findings illustrate that emodin and aloe-emodin might serve
as estrogen receptor modulators with different molecular
mechanisms. The therapeutic application of these two com-
pounds should be investigated further in the future.
Anthraquinones are phytoestrogens that have been
demonstrated to possess anticancer properties through the
inhibition of cell proliferation, the induction of apoptosis,
and the prevention of metastasis [1]. The effects of the
anthraquinone derivatives emodin and aloe-emodin have
been extensively investigated in several cancer types through
studies on their signaling targets. Emodin has been reported
to sensitize Her2/neu-overexpressing lung cancer cells to
chemotherapeutic treatments and to suppress Her2/neu-
overexpressing breast cancer growth by inhibiting tyrosine
kinase activity [32–34]. Notably, emodin has been shown to
downregulate androgen receptor (AR) and inhibit prostate
cancer growth [5], suggesting that there is a connection
between anthraquinone derivatives and steroid receptor in
hormone-related cancers. Although the estrogenic ability
of emodin is higher than that of aloe-emodin, as deter-
mined by ER𝛼 binding studies, the antiproliferation effect
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of aloe-emodin is more efficient than that of emodin in
breast cancer cells [7]. Kang et al. also showed that the
cytotoxicity of aloe-emodin is higher in ER𝛼-positive cells
than in ER𝛼-negative cells [7]. These observations suggest
that aloe-emodin might be a stronger inhibitor of ER𝛼-
positive cancer cell growth than emodin.
The goal of this study was to investigate the differences
between emodin and aloe-emodin in their efficiency and
mechanism of blocking breast cancer cell growth. Our data
showed that aloe-emodin is a more potent growth inhibitor
than emodin and has a unique mechanism for the growth
inhibition of breast cancer cells. MCF-7 cell growth was
abolished following treatment with 12.5 𝜇M aloe-emodin for
6 days, and only 50% of cells survived at 25𝜇M aloe-emodin
treatment for 4 days (Figure 1(b)). Although a previous study
suggested that the IC
50
of aloe-emodin is 12.6 ± 0.83 𝜇g/mL
(approximately 46 𝜇M) on MCF-7 cells [7], the IC
50
of
aloe-emodin in our system was only approximately 25 𝜇M
(Figure 1(d)). With regard to side effects on normal cells, the
previous report indicated that 25 𝜇M aloe-emodin is a more
significant proliferation inhibitor in human skin epidermoid
carcinoma cells than in noncancerous cells [35]. However,
aloe-emodin did not significantly affect the proliferation of
MDA-MB-453 ER𝛼-negative cells (Figure 1(f)). The overex-
pression of ER𝛼 in MCF-7 cells increased the sensitivity
to aloe-emodin treatment (Figure 1(h)). These results are
consistent with previous findings that aloe-emodin has a
higher cytotoxic potential to MCF-7 (ER𝛼-positive) cells
than to MDA-MB-231 (ER𝛼-negative) cells [7]. A low dosage
(10 𝜇M) of aloe-emodin [6] showed that both cell growth
(Figures 1(b) and 1(d)) and ER𝛼 activation (Figure 3(d)) were
significantly repressed by aloe-emodin in a dose-dependent
manner, even at low dosages (6 𝜇M). Additionally, aloe-
emodin treatment reduced ER𝛼 protein levels not only in
total lysates (Figures 2(c) and 2(d)) but also in nuclear and
cytoplasmic fractions (Figure 3(b)). In the nuclear and cyto-
plasmic fractions, the impact of aloe-emodin treatment on
cytoplasmic ER𝛼 levels seems stronger than that on nuclear
ER𝛼 levels (Figure 3(b)). As shown in Figures 2 and 4, we con-
clude that the decrease in ER𝛼 levels induced by aloe-emodin
was due to protein degradation. This correlates with ER𝛼
proteasome-dependent degradation because of the observed
elevation in ubiquitin-conjugated levels (Figure 5(c)). Inter-
estingly, the dissociation of ER𝛼 and HSP90 was increased
by aloe-emodin treatment (Figure 5(a)), and ER𝛼 released
from HSP90 protection was subjected to ubiquitination for
degradation rather than translocation to the nucleus for
activation (Figure 6(b)). These phenomena are similar to
the actions of antiestrogens such as ICI 164384, ICI 182780,
and RU 58668, which may induce ER𝛼 degradation and
result in rapid turnover [24]. As a ligand with an inhibitory
effect on ER𝛼, we suggest that aloe-emodin might qualify as
an estrogen receptor modulator to negatively regulate ER𝛼
activity and inhibit breast cancer cell growth.
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The effect of emodin was also investigated in this study.
Although the inhibitory effects of emodin on breast cancer
growth and ER𝛼 activation were similar to those of aloe-
emodin, the molecular mechanism of emodin inhibition was
unexpectedly distinct. In Figures 1(a) and 1(c), the inhibitory
potency of emodin onMCF-7 cell growth was lower than that
of aloe-emodin (Figures 1(b) and 1(d)). Interestingly, emodin
significantly suppressed cell proliferation of the ER𝛼-negative
cell line MDA-MB-453 (Figure 1(e)). Because emodin may
act as a tyrosine kinase inhibitor by inhibiting the binding of
Her2/neu andHSP90, thereby depletingHer2/neu via protea-
somal degradation [36], it is possible that emodinmight differ
in its effect on the growth of MDA-MB-453 cells (which are
characterized by Her2 overexpression) in ER𝛼-independent
regulation in comparison to aloe-emodin. Like aloe-emodin,
emodin targeted ER𝛼 by proteasomal degradation (Figures 2
and 4); however, the degradation pathway was independent
of HSP90/ER𝛼 dissociation and ubiquitination (Figures 5(b)
and 5(d)). Although the ubiquitin-proteasome degradation
is an important process for modulation of many proteins,
recent studies demonstrate that the proteasome-dependent
protein degradation possibly goes through ubiquitination-
independent pathway [37, 38]. Previous reports indicate
that the estrogenic activity of emodin is higher than that
of aloe-emodin [6, 7]. Our ERE reporter assay results
showed that emodin induced the inhibition of ER𝛼 activation
only at high dosages (over 25 𝜇M, Figure 3(c)), whereas
the aloe-emodin data showed inhibitory effects starting at
low dosages (6 𝜇M, Figure 3(d)). Notably, emodin treat-
ment led to a slight increase in ER𝛼 activation at 6 and
12.5 𝜇M, which differed from the aloe-emodin treatment
results (Figure 3(c)). Unlike aloe-emodin, emodin treatment
elevated nuclear ER𝛼 protein levels in the presence of MG132,
similar to the effects of estradiol benzoate (EB) treatment
(Figure 6(c)). Taken together with the data in Figure 3(a),
we suggest that emodin, using a distinct mechanism from
aloe-emodin, might cause ER𝛼 shuttling into the nucleus
and subsequently promote nuclear ER𝛼 degradation through
ubiquitination-independent pathway, whereas cytoplasmic
ER𝛼 is less affected. This hypothesis is similar to previous
studies indicating that the chemical structure of the ligand
directly affects the nuclear fate and protein turnover rate of
ER𝛼 independently of transcriptional regulation [39]. These
observations suggest that the essential difference between
emodin and aloe-emodin lies in the mechanism of ER𝛼
regulation and Her2 inhibition.
In conclusion, we provide evidence showing that the anti-
cancer mechanisms of the anthraquinone derivatives emodin
and aloe-emodin are mediated via an ER𝛼-dependent path-
way in breast cancer cells. Although emodin and aloe-emodin
display distinct differences in efficiency and ER𝛼 activation
mechanism on breast cancer cell growth, both compounds
are potential selectively therapeutic treatments for breast
cancer.
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